Based on the Pfizer Inc stock forecast from 12 analysts, the average analyst target price for Pfizer Inc is USD 35.00 over the next 12 months. Pfizer Inc’s average analyst rating is Buy . Stock Target Advisor’s own stock analysis of Pfizer Inc is Slightly Bearish, which is based on 4 positive signals and 9 negative signals. At the last closing, Pfizer Inc’s stock price was USD 26.72. Pfizer Inc’s stock price has changed by -2.34% over the past week, -8.37% over the past month and -8.68% over the last year.
No recent analyst target price found for Pfizer Inc
No recent average analyst rating found for Pfizer Inc
Company Overview Pfizer Inc
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as has strategic clinical collaboration with Acepodia Inc. for the development of antibody-cell conjugation-based cell therapies in autoimmune diseases. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York. Read Less
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and w...Read More
Frequently Asked Questions About Pfizer Inc (PFE) Stock
Based on ratings from 12 analysts Pfizer Inc's stock is Buy . Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 10 buy, sell and 12 hold ratings.
PFE stock's dividend yield is 5.82%.
Our analysis grades PFE stock's dividend yield at B. This means that PFE stock's dividend yield is above 86% of the stocks in the Drug Manufacturers - General sector in the NYE exchange.
Based on this PFE may be a good dividend stock for its sector.
Based on targets from 12 analysts, the average taret price for PFE is USD 35.00 over the next 12 months. The maximum analyst target price is USD 45 while the minimum anlayst target price is USD 27.
Unfortunately we do not have enough data on PFE's stock to indicate if its overvalued.
The last closing price of PFE's stock was USD 26.72.
The most recent market capitalization for PFE is USD 163.54B.
Based on targets from 12 analysts, the average taret price for PFE is projected at USD 35.00 over the next 12 months.
This means that PFE's stock price may go up by +30.99% over the next 12 months.
We can't find any ETFs which contains Pfizer Inc's stock.
As per our most recent records Pfizer Inc has 88,000 Employees.
Pfizer Inc's registered address is 66 Hudson Boulevard East, New York, NY, United States, 10001-2192.
You can get more information about it from Pfizer Inc's website at https://www.pfizer.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Underpriced compared to book value
The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior Dividend Growth
This stock has shown top quartile dividend growth in the previous 5 years compared to its sector
What not to like
Poor capital utilization
The company management has delivered below median return on invested capital in the most recent 4 quarters compared to its peers.
Poor return on assets
The company management has delivered below median return on assets in the most recent 4 quarters compared to its peers.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Pfizer Inc (PFE) Stock
Based on ratings from 12 analysts Pfizer Inc's stock is Buy . Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 10 buy, sell and 12 hold ratings.
PFE stock's dividend yield is 5.82%.
Our analysis grades PFE stock's dividend yield at B. This means that PFE stock's dividend yield is above 86% of the stocks in the Drug Manufacturers - General sector in the NYE exchange.
Based on this PFE may be a good dividend stock for its sector.
Based on targets from 12 analysts, the average taret price for PFE is USD 35.00 over the next 12 months. The maximum analyst target price is USD 45 while the minimum anlayst target price is USD 27.
Unfortunately we do not have enough data on PFE's stock to indicate if its overvalued.
The last closing price of PFE's stock was USD 26.72.
The most recent market capitalization for PFE is USD 163.54B.
Based on targets from 12 analysts, the average taret price for PFE is projected at USD 35.00 over the next 12 months.
This means that PFE's stock price may go up by +30.99% over the next 12 months.
We can't find any ETFs which contains Pfizer Inc's stock.
As per our most recent records Pfizer Inc has 88,000 Employees.
Pfizer Inc's registered address is 66 Hudson Boulevard East, New York, NY, United States, 10001-2192.
You can get more information about it from Pfizer Inc's website at https://www.pfizer.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for PFE !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
